Literature DB >> 18795070

Tpl-2/Cot and COX-2 in breast cancer.

Zuzana Krcova1, Jiri Ehrmann, Veronika Krejci, Aris Eliopoulos, Zdenek Kolar.   

Abstract

BACKGROUND: Breast cancer is the most common cancer in women worldwide and although mortality (129,000/year) stagnates, incidence (370,000/year) is increasing. In addition to histological type, grade, stage, hormonal and c-erbB2 status there is therefore a strong need for new and reliable prognostic and predictive factors. METHODS AND
RESULTS: This minireview focuses on two potential prognostic and predictive candidates Tpl2/Cot and COX-2 and summarise information about them.
CONCLUSION: Tumor progression locus 2 (Tpl2/Cot) is a serine/threonine protein kinase belonging to the family of MAP3 kinases. Activated Tpl2/Cot leads to induction of ERK1/2, JNK, NF-kappaB and p38MAPK pathways. The first study on Tpl2/Cot mRNA in breast cancer showed its increase in 40 % of cases of breast cancer but no available data exist on protein expression. Cyclo-oxygenase 2 (COX-2) is inducible by growth and inflammatory factors and contributes to the development of various tumours. Expression of COX-2 in breast cancer varied from 5-100 % in reviewed papers with significantly higher values in poorly differentiated tumours. Tpl2/Cot and COX-2 have their importance in different intracellular pathways and some of these are involved in cancer development. Briefly, the results from recent studies suggest that Tpl2/Cot and COX-2 could be prognostic factors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795070     DOI: 10.5507/bp.2008.003

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  10 in total

1.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Authors:  Giuliana Cássia Morrone Taromaru; Vilmar Marques DE Oliveira; Maria Antonieta Longo Galvão Silva; Wagner Ricardo Montor; Fabio Bagnoli; José Francisco Rinaldi; Tsutomu Aoki
Journal:  Oncol Lett       Date:  2011-12-21       Impact factor: 2.967

3.  7,3',4'-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet B-induced skin cancer by targeting Cot and MKK4.

Authors:  Dong Eun Lee; Ki Won Lee; Sanguine Byun; Sung Keun Jung; Nury Song; Sung Hwan Lim; Yong-Seok Heo; Jong Eun Kim; Nam Joo Kang; Bo Yeon Kim; G Tim Bowden; Ann M Bode; Hyong Joo Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

4.  Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.

Authors:  Berrin Tunca; Gulcin Tezcan; Gulsah Cecener; Unal Egeli; Abdullah Zorluoglu; Tuncay Yilmazlar; Secil Ak; Omer Yerci; Ersin Ozturk; Gorkem Umut; Turkkan Evrensel
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-16       Impact factor: 4.553

5.  Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.

Authors:  Vasiliki Koliaraki; Manolis Roulis; George Kollias
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

6.  Astrocyte elevated gene-1 and breast cancer (Review).

Authors:  Chuan Wang; Qifeng Yang
Journal:  Oncol Lett       Date:  2011-03-15       Impact factor: 2.967

7.  Aberrant expression of COT is related to recurrence of papillary thyroid cancer.

Authors:  Jandee Lee; Seonhyang Jeong; Jae Hyun Park; Cho Rok Lee; Cheol Ryong Ku; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Dong Yeob Shin; Eun Jig Lee; Woong Youn Chung; Young Suk Jo
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

Review 8.  Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer.

Authors:  Hye Won Lee; Han Yong Choi; Kyeung Min Joo; Do-Hyun Nam
Journal:  Int J Mol Sci       Date:  2015-02-25       Impact factor: 5.923

9.  Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Authors:  Laura Boldrini; Mirella Giordano; Adele Servadio; Cristina Niccoli; Pietro Bertoglio; Marco Lucchi; Franca Melfi; Alfredo Mussi; Gabriella Fontanini
Journal:  Mol Med Rep       Date:  2017-04-03       Impact factor: 2.952

10.  Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.

Authors:  Guanwen Wang; Juan Wang; Antao Chang; Dongmei Cheng; Shan Huang; Dan Wu; Sherona Sirkisoon; Shuang Yang; Hui-Kuan Lin; Hui-Wen Lo; Rong Xiang; Peiqing Sun
Journal:  Oncogene       Date:  2020-09-28       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.